27660855|t|Discovery of Orally Efficacious Phosphoinositide-3-Kinase delta Inhibitors with Improved Metabolic Stability
27660855|a|Aberrant signaling of phosphoinositide-3-kinase delta (PI3K-delta) has been implicated in numerous pathologies including hematological malignancies and rheumatoid arthritis. Described in this manuscript is the discovery, optimization and in vivo evaluation of a novel series of pyridine-containing PI3K-delta inhibitors. This work led to the discovery of 35, a highly selective inhibitor of PI3K-delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.
27660855	13	19	Orally	T082	UMLS:C0226896
27660855	32	63	Phosphoinositide-3-Kinase delta	T103	UMLS:C1450115
27660855	64	74	Inhibitors	T103	UMLS:C0014432
27660855	80	88	Improved	T033	UMLS:C0184511
27660855	109	127	Aberrant signaling	T038	UMLS:C3537152
27660855	131	162	phosphoinositide-3-kinase delta	T103	UMLS:C1450115
27660855	164	174	PI3K-delta	T103	UMLS:C1450115
27660855	208	219	pathologies	T038	UMLS:C0677042
27660855	230	256	hematological malignancies	T038	UMLS:C0376545
27660855	261	281	rheumatoid arthritis	T038	UMLS:C0003873
27660855	347	354	in vivo	T082	UMLS:C1515655
27660855	355	365	evaluation	T058	UMLS:C0220825
27660855	387	406	pyridine-containing	T103	UMLS:C0576798
27660855	407	417	PI3K-delta	T103	UMLS:C1450115
27660855	418	428	inhibitors	T103	UMLS:C0014432
27660855	464	466	35	T103	UMLS:C1254351
27660855	487	496	inhibitor	T103	UMLS:C0014432
27660855	500	510	PI3K-delta	T103	UMLS:C1450115
27660855	587	599	rodent model	T038	UMLS:C1519106
27660855	603	623	rheumatoid arthritis	T038	UMLS:C0003873